ClinicalTrials.gg
Sign In
CompletedNCT02603315VITMPMUpdated Jun 1, 2016

Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)

An observational study in Malignant Pleural Mesotheliomas, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 39 Years to 84 Years. Per ClinicalTrials.gov, last updated 2016-06-01.

Sponsored by Ain Shams University · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
50
Ages
39 Years to 84 Years
Sex
All
01

Study summary

The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .

Read the detailed description

This is a randomized controlled retrospective study through Examination of paraffin blocks of the patient selected to be included in the study for assessment of the selected vascularity marker of malignant pleural mesothelioma of both types . The CD74 (LN2) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed paraffin-embedded tissue sections using Immunohistochemistry test methods.

02

Conditions studied

  • Malignant Pleural Mesotheliomas
03

In context

Mesothelioma, Malignant

418 studies on the registry are indexed under Mesothelioma, Malignant; 73 are open to participants now.

This study's enrollment of 50 is below the median of 119 across 50 observational studies indexed under Mesothelioma, Malignant.

Browse Mesothelioma, Malignant studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,932 studies on the registry; 433 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Ain Shams University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
39 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Egyptian patients with confirmed malignant pleural mesothelioma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathological confirmation of malignant pleural mesothelioma .
  • Full clinical data.

  • Availability for follow up: Personal communication will be attempted in order to collect missing information.

    3-The files of all patients will be reviewed to analyze the following :

  • Operative data if done .
  • Pathological review and immunohistochemistry.
  • Laboratory investigations: (routine investigations: complete blood picture,liver and renal function test)
  • Radiological investigations:( CXR and CT-chest, Abdominal and pelvic U\S and MRI ).
  • Treatment protocols applied: Radiotherapy and Chemotherapy.
  • Response and survival after treatment .

Exclusion criteria

Exclusion Criteria:

  • cases not receive chemotherapy ,on available of evaluation after treatment
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
50 participants (actual)
Patient registry
No

Interventions

  • Othermarker CD74 and vascular endothelial growth factor VEGF

    correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment

06

What researchers measure

Primary outcomes

  1. to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival

    The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment

    Time frame: 3-4 months

Secondary outcomes

  1. assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result of CD 74

    The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment

    Time frame: 3-4 months

07

Study locations

1 site
  • Ain Shams University Hospital
    Cairo, Egypt
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2015
First posted
Nov 11, 2015
Start
Oct 2015
Primary completionActual
May 2016
CompletionActual
May 2016
Last update
Jun 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02603315
Lead sponsor
Ain Shams University
Responsible party
Muna Sami Jassim (Doctor in clinical oncology and nuclear medicine department, Ain Shams University) — Principal investigator
First posted
Nov 11, 2015
Start date
Oct 2015
Primary completion
May 2016
Completion
May 2016
Last update
Jun 1, 2016

Study contacts

Amr S Saad, MD
study director · Ain Shams University
Mahmoud Ellithy, MD
study chair · Ain Shams University
Doaa Atef, MD
study director · Ain Shams University
Hoda Abougabal, MD
study director · Ain Shams University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Mesothelioma, Malignant →

Other studies from this sponsor

Ain Shams University →

Start the discussion